Original Mycosis Fungoides Cooperative Group staging system for cutaneous T-cell lymphoma2
| Stage . | Tumor (T) . | Lymph node (N) . | Metastasis (M) . | Blood (B)* . |
|---|---|---|---|---|
| Early stages | ||||
| IA | T1: patches/plaques over < 10% of skin surface | N0: no palpable lymphadenopathy or histologic involvement | M0: no visceral involvement | B0: < 5% SC; B1: > 5% SC and no more than one of the following: T-cell clone in blood; SC count > 1 × 109/L; CD4:CD8 ≥ 10; B2: > 5% SC AND T-cell clone in blood AND either SC count > 1 × 109/L or CD4:CD8 ≥ 10* |
| IB | T2: patches/plaques over > 10% of skin surface | N0 | M0 | |
| IIA | T1 or T2 | N1: palpable lymphadenopathy, no histologic involvement | M0 | |
| Advanced stages | ||||
| IIB | T3: tumors | N0 or N1 | M0 | |
| III | T4: erythroderma | N0 or N1 | M0 | |
| IVA | T1-T4 | N2: no palpable lymphadenopathy but histologic involvementORN3: palpable lymphadenopathy and histologic involvement | M0 | |
| IVB | T1-T4 | N0-N3 | M1: histologic visceral involvement | |
| Stage . | Tumor (T) . | Lymph node (N) . | Metastasis (M) . | Blood (B)* . |
|---|---|---|---|---|
| Early stages | ||||
| IA | T1: patches/plaques over < 10% of skin surface | N0: no palpable lymphadenopathy or histologic involvement | M0: no visceral involvement | B0: < 5% SC; B1: > 5% SC and no more than one of the following: T-cell clone in blood; SC count > 1 × 109/L; CD4:CD8 ≥ 10; B2: > 5% SC AND T-cell clone in blood AND either SC count > 1 × 109/L or CD4:CD8 ≥ 10* |
| IB | T2: patches/plaques over > 10% of skin surface | N0 | M0 | |
| IIA | T1 or T2 | N1: palpable lymphadenopathy, no histologic involvement | M0 | |
| Advanced stages | ||||
| IIB | T3: tumors | N0 or N1 | M0 | |
| III | T4: erythroderma | N0 or N1 | M0 | |
| IVA | T1-T4 | N2: no palpable lymphadenopathy but histologic involvementORN3: palpable lymphadenopathy and histologic involvement | M0 | |
| IVB | T1-T4 | N0-N3 | M1: histologic visceral involvement | |
This staging system does not take into account B classification in determining overall clinical stage.